Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Previous studies have suggested that the mivacurium infusion rate to maintain target twitch depression is greater in children than in adults, and that there is only a limited relationship between pseudocholinesterase activity and mivacurium infusion rate in children. We therefore examined whether mivacurium infusion rates are larger in children than in adults, and whether pseudocholinesterase activity influences mivacurium infusion rate in children. In 20 children aged 1-9 yr, mechanical twitch response to ulnar nerve train-of-four stimulation was measured; concurrent data were obtained in 14 adults aged 18-58 yr. All patients were anesthetized with N2O and isoflurane, 0.75 minimum alveolar anesthetic concentration (MAC) (age-adjusted). Mivacurium was infused at constant rates for > 15 min targeting 50% and 90% twitch depression. The Hill equation was fit to the resulting values for twitch depression versus mivacurium infusion rate to predict infusion rates producing 50% and 90% twitch depression (IR50 and IR90, respectively). The relationship of IR50 and IR90 to pseudocholinesterase activity was determined by linear regression; values for children and adults were compared by analysis of covariance. For children, IR50 (r2 = 0.22, P = 0.038) but not IR90 (r2 = 0.11 P = 0.21) was related to pseudocholinesterase activity. Infusion rates were approximately twice as large in children as in adults. We confirm that mivacurium infusion rates are larger in children than in adults and demonstrate a relationship between pseudocholinesterase activity and infusion rates.
 ...
PMID:Does age or pseudocholinesterase activity predict mivacurium infusion rate in children? 871 23

A clinical trial was designed to evaluate the effects of diminazene aceturate and its stabiliser antipyrine on serum pseudocholinesterase (PChE) and red blood cell acetylcholinesterase (RBC AChE) in dogs with babesiosis. The trial was conducted on naturally occurring, uncomplicated cases of babesiosis (n = 20) that were randomly allocated to groups receiving a standard therapeutic dose of diminazene aceturate with antipyrine stabiliser (n = 10) or antipyrine alone (n = 10). Blood was drawn immediately before and every 15 minutes for 1 hour after treatment. Plasma PChE showed a 4% decrease between 0 and 60 min within the treatment group (p < 0.05). No statistically significant differences were found between the treatment and control groups at any of the time intervals for PChE. There was an increase in RBC AChE activity at 15 min in the treatment group (p < 0.05). No significant differences were found between the treatment and control groups at any time interval for RBC AChE. In view of the difference in PChE, samples from additional, new cases (n = 10) of canine babesiosis were collected to identify the affect of the drug over 12 hours. No significant depression was identified over this time interval. The results suggests that the underlying mechanism in producing side-effects, when they do occur, is unlikely to be through cholinesterase depression.
 ...
PMID:The effect of diminazene aceturate on cholinesterase activity in dogs with canine babesiosis. 956 93

We studied the effect of 17 commonly used drugs, including prescription and over-the-counter medications, on the activity of serum pseudocholinesterase (PCE) in vitro. Normal pooled human serum was incubated for 120 minutes at 37 degrees C with therapeutic serum concentrations of prescription and over-the-counter drugs, and the postincubation PCE activity was measured. Morphine, quinidine, and thioridazine depressed PCE activity by more than 5% while no or negligible effect was noted following incubation with acetaminophen, chlordiazepoxide, chlorpromazine, desipramine, doxepin, imipramine, methamphetamine, nortriptyline, phenobarbital, phenytoin, procainamide, salicylic acid, theophylline, and valproic acid. Depression of PCE activity can prolong the half-life of coadministered agents with metabolism mediated by PCE.
 ...
PMID:Studies of the inhibition of serum pseudocholinesterase activity in vitro by commonly used drugs. 1604 Feb 93

Clinically significant pseudocholinesterase deficiency is a relatively uncommon disorder, but when present, it presents clinicians with challenges regarding medication administration. This is especially true in cases of patients receiving electroconvulsive therapy (ECT), as the presence of pseudocholinesterase deficiency limits the use of certain muscle relaxants. The authors describe a patient receiving ECT for treatment of his depression, who also possessed an unsuspected pseudocholinesterase deficiency. This was diagnosed after the patient was given succinylcholine, did not spontaneously recover motor function, and eventually required intubation. Subsequent ECT treatments were then managed with an alternative muscle relaxant which was not dependent on pseudocholinesterase for termination of action.
 ...
PMID:Pseudocholinesterase deficiency and electroconvulsive therapy. 1780

As the transgender patient population continues to grow, health care providers will need to become aware of elements unique to the transgender community in order to provide the highest quality of care. Neuromuscular blockade with succinylcholine is routinely administered to patients undergoing electroconvulsive therapy (ECT). Decreased amounts or activity of pseudocholinesterase in serum can lead to prolonged duration of muscle paralysis. Causes of reduced action by pseudocholinesterase include genetically abnormal enzymes, reduced hepatic production, pregnancy, and various drug interactions. Estrogen supplementation taken by transitioning patients may affect the duration of neuromuscular blockade.This is a case of a 32-year-old male-to-female transgender patient with prolonged apnea following ECT treatment for severe, refractory depression. Further investigation revealed the patient was on estrogen therapy as a part of her transition and laboratory testing demonstrated reduced serum pseudocholinesterase activity. Further laboratory testing demonstrated reduced serum pseudocholinesterase activity. Succinylcholine dosing was titrated to an appropriate level to avoid prolonged apnea in subsequent ECT treatments. Physicians and other health care providers are faced with a unique population in the transgender community and must be aware of distinctive circumstances when providing care to this group. Of specific interest, many transitioning and transitioned patients can be on chronic estrogen supplementation. Neuromuscular blockade in those patients require attention from the anesthesiology care team as estrogen compounds may decrease pseudocholinesterase levels and lead to prolonged muscle paralysis from succinylcholine.
 ...
PMID:Electroconvulsive Therapy Considerations for Transgendered Patients. 2800 18


<< Previous 1 2